Venture capital firm

Atalanta Therapeutics

Biotechnology company developing RNA interference treatments for neurodegenerative and other brain diseases

Visit Website Get introducedRequest an introduction Write a Review

TrustList summary

Atalanta Therapeutics is a biotechnology company working on medicines for diseases of the central nervous system. It was created in response to the need for treatments for neurodegenerative conditions.

Its science builds on the founders' work on RNA interference, an approach that aims to stop a disease at its source by silencing the gene behind it.

What Atalanta Therapeutics offers

RNAi therapies: investigational drugs based on branched siRNA.
Huntington's disease work: gene silencing aimed at halting the disease.
Epilepsy research: preclinical data on a therapy for KCNT1-related epilepsy.
Scientific information: explainers on RNA interference and its own approach.

Who it works with

Patients with neurological conditions, served through drug development rather than direct services. Its site carries press releases and leadership news.

Key facts

Focus: central nervous system diseases
Technology: branched siRNA and RNA interference
Stage: investigational and preclinical programmes

Summary written by TrustList from the business's own published information, Sep 2026.

Gallery

2 images - click to enlarge

Categories & features

Rankings

Atalanta Therapeutics is ranked on 2 TrustList rankings: #12 on 1 and #30 on 1.

Every ranking orders its listings by their reviews, how complete the profile is and the Trust Score. Atalanta Therapeutics has no reviews yet and 3 of the 10 profile details we look for. Where no listing on a page has been reviewed, the order follows the profiles alone.

Venture capital firm · 2 rankings

#12of 35
Amsterdam
Of the 35 here, 7 also cover fintech and 4 also cover series a; 12 also work in London and 9 also work in New York City.
Behind Ampersand Capital Partners, ahead of Avedon Capital Partners.
#30of 110
Boston
Of the top 69 here, 11 also cover biotech and 10 also cover seed stage; 19 also work in San Francisco and 17 also work in Silicon Valley.
Behind Ampersand Capital Partners, ahead of Atlas Venture.